GATA2 Deficiency: Early Identification for Improved Clinical Outcomes

Kristen Cole

Daniele Avila

Mark Parta

Bazetta Schuver

Steven Holland

Nirali Shah

Dennis Hickstein

GATA2 deficiency, myelodysplastic syndrome, acute myeloid leukemia
CJON 2019, 23(4), 417-422. DOI: 10.1188/19.CJON.417-422

Background: Patients with GATA2 deficiency present with nontuberculous mycobacterial infections, severe viral infections (particularly refractory human papillomavirus disease), lymphedema, myelodysplastic syndrome (MDS), and acute myeloid leukemia. Patients with GATA2 deficiency who undergo allogeneic hematopoietic stem cell transplantation prior to the development of life-threatening infections or cytogenetic abnormalities may have optimal clinical outcomes.

Objectives: The aim of this article is to determine ways in which oncology nurses can identify GATA2 deficiency in patients early and optimize treatment decisions.

Methods: A case study is presented of a 33-year-old man with recurrent infections and MDS and his two sons, all of whom were found to have the same GATA2 mutation.

Findings: Oncology nurses play an important role in early detection and identification by interviewing patients and obtaining a complete and thorough family history.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.